BRCA1 and ovarian carcinoma: The SOLO2/ENGOT-Ov21 study (NCT01874353) showed that maintenance treatment with olaparib (300 mg twice daily) in patients with platinum-sensitive, recurrent ovarian cancer and BRCA1/2 mutation significantly improved progression-free survival (19.1 vs. 5.5 months, HR = 0.30, p < 0.0001) compared to placebo.